Efgartigimod alfa - argenx
Alternative Names: ARGX-113; EFG PH20 SC; Efgartigimod - argenx; Efgartigimod alfa-fcab - argenx; efgartigimod PH20; efgartigimod PH20 SC; PH20 SC; VYVDURA; VYVGART; VYVGART HYTRULOLatest Information Update: 21 Aug 2024
At a glance
- Originator arGEN-X
- Developer argenx; Medison; ZAI Lab
- Class Anti-inflammatories; Antiarrhythmics; Immunoglobulin Fc fragments; Monoclonal antibodies; Skin disorder therapies; Urologics
- Mechanism of Action Neonatal Fc receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic inflammatory demyelinating polyradiculoneuropathy; Myasthenia gravis
- Registered Idiopathic thrombocytopenic purpura
- Phase III Bullous pemphigoid; Graves ophthalmopathy; Myositis; Pemphigus
- Phase II Lupus nephritis; Membranous glomerulonephritis; Sjogren's syndrome
- Clinical Phase Unknown Renal transplant rejection
- Preclinical Immune-mediated necrotising myopathy
- Discontinued Anti-neutrophil cytoplasmic antibody-associated vasculitis; Postural orthostatic tachycardia syndrome
Most Recent Events
- 16 Aug 2024 Argenx plans a phase III trial for Myasthenia gravis in September 2024 (SC) (NCT06558279)
- 14 Aug 2024 Argenx plans the phase III advance NEXT trial in Idiopathic thrombocytopenic purpura (IV) in October 2024 (NCT06544499)
- 01 Aug 2024 University of South Florida plans a phase II trial for Stiff Person Syndrome in USA (SC) in August 2024 (NCT06528392)